Skip to main content
Explore URMC
menu

Zhenqiang Yao, B.Med., Ph.D.

Contact Information

Phone Numbers

Office: (585) 273-4129

Fax: (585) 756-4468

Faculty Appointments

Biography

Dr. Yao's research interests include bone cell biology, osteoporosis, osteoarthritis/rheumatoid arthritis, bone metastasis cancer, and bone histomorphometry.

Research

Dr. Yao's research focuses on the mechanisms whereby cytokines regulate osteoclast and osteoblast differentiation and function through TRAF3-NF-kappaB signaling in vitro and in animal models of rheumatoid arthritis (RA), osteoporosis and bone metastatic cancers.
1. RA: Macrophages act as the master orchestrator of the joint damage in RA since 1) macrophages are the major producers of pro-inflammatory cytokines that mediate the local and systemic inflammation; 2) Macrophages induce angiogenesis to form inflamed pannus that invade articular cartilage and bone; and 3) Macrophages differentiate into osteoclasts to erode cartilage and bone of the joints. TNF strongly stimulates the differentiation of inflammatory macrophages with enhanced osteoclast forming potential and increased production of inflammatory factors through NF-kappaB RelB. Thus, depletion of TNF-induced inflammatory macrophages targeting RelB could be a novel strategy for RA therapy.
2. Osteoporosis is initiated by the increased bone resorption due to the excessive activity of osteoclasts associated with the un-matched bone formation. Anti-resorptive and anabolic drugs are available for the treatment of osteoporosis. The commonly used anti-resorptive drugs can result in bone necrosis, limiting their use. Teriparatide is the only FDA approved agent that stimulates new bone formation however its use is limited to 2 years due to the potential to induce osteosarcoma and it is suggested to be contraindicated in patients with bone metastatic cancers. Combined therapy with current anti-resorptive and anabolic drug does not offer advantages over the use of the single agent alone. We are developing new agents with dual anti-resorptive and anabolic effect targeting TRAF3-non-canonical NF-?B signaling proteins for the therapy of osteoporosis.
3. Bone is one of the most common sites of cancer metastasis, particular, in breast cancer and prostate cancer. The development and progression of bone metastatic cancers depend on cancer-bone cell (osteoclast and osteoblast) interactions. Cancer cells produce factors, such as PTHrP, IL-6 and IL-8, to enhance osteoclast formation and bone destruction by promoting RANKL production by osteoblastic cells. Factors released during osteolysis from bone matrix, such as TGFbeta1, IGF and FGF, stimulates tumor growth. Some of these released factors, such as TGFbeta1, also inhibit bone formation. Our goal is to develop an "All-in-One" agent that simultaneously induces cancer cell death, inhibit osteoclast and stimulate osteoblast differentiation to prevent breast cancer bone metastasis.

Credentials

Education

1986
B.Med. | Luoyang Medical College
Medicine

1993
Master | Kunming Medical College
Orthopedic Surgery

2016
PhD | University of Westminster
Biomedical Science

Post-doctoral Training & Residency

2003 - 2007
Postdoctoral Research Associate, Department of Pathology, University of Rochester Medical Center

05/2001 - 04/2003
Post-doc Researcher, Laboratore de Biologie et Biochimie du Tissue Osseux, Institut National de la Sante et de la Recherche Medicale (INSERM), Faculty de Medecine, Saint-Etienne, France

1986 - 1990
Resident/General Surgery, Department of Surgery, Kaifeng First Hospital, Henan, China

VIEW ALL expand_more

Awards

2021
The Mid-Career Faculty Travel Grant
Sponsor: American Society for Bone and Mineral Research

2007
Young Investigator Award
Sponsor: American Society for Bone and Mineral Research

2006
Young Investigator Award
Sponsor: International Society of Bone Morphology

VIEW ALL expand_more

Patents

Patent Title: Phosphonate-Chloroquine Conjugates and Methods Using Same
Patent #: 10,660,884
Issue Date: May 26, 2020
Country: United States
Invented By: Robert K Boeckman, Jr., Brendan Boyce, Frank (Hal) Ebetino, Lifeng Xiao, Zhenqiang Yao

Publications

Journal Articles

9/2/2020
Sun S, Tao J, Sedghizadeh PP, Cherian P, Junka AF, Sodagar E, Xing L, Boeckman RK, Srinivasan V, Yao Z, Boyce BF, Lipe B, Neighbors JD, Russell G, McKenna CE, Ebetino FH. "Bisphosphonates for delivering drugs to bone." British journal of pharmacology.. 2020 Sep 2; Epub 2020 Sep 02.

6/22/2020
Xing L, Ebetino FH, Boeckman RK, Srinivasan V, Tao J, Sawyer TK, Li J, Yao Z, Boyce BF. "Targeting anti-cancer agents to bone using bisphosphonates." Bone.. 2020 Jun 22; :115492. Epub 2020 Jun 22.

4/24/2020
Lei W, Duan R, Li J, Liu X, Huston A, Boyce BF, Yao Z. "The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice." Scientific reports.. 2020 Apr 24; 10(1):7004. Epub 2020 Apr 24.

Books & Chapters

2021
Chapter Title: RANKL-Based Osteoclastic Assay from Murine Bone Marrow Cells
Book Title: Skeletal Development and Repair. Methods in Molecular Biology
Author List: Yao Z, Xing L and Boyce B.
Published By: Springer 2021

2020
Chapter Title: Osteoclast Signal Transduction Pathways: The RANKL/RANK System.
Book Title: Encyclopedia of Bone Biology
Author List: Yao Z, Boyce B.
Published By: Elsevier 2020

2020
Chapter Title: Translational Pharmacology in the Development of RANKL Inhibitors
Book Title: Encyclopedia of Bone Biology
Author List: Boyce B, Yao Z.
Published By: Elsevier 2020

VIEW ALL PUBLICATIONS